超声风险分类对细胞学不确定甲状腺结节分子检测预测恶性肿瘤风险的效应修饰作用
这项前瞻性队列研究纳入343例患者的375个Bethesda III/IV甲状腺结节,评估Afirma GSC和ThyroSeq v3在不同ATA超声风险分类下的诊断性能。在超声低/中疑结节中,分子检测可显著改变恶性率;但在ATA高疑结节中,阳性分子结果未显著提高恶性率。
要点
- ATA高疑结节中,可疑Afirma GSC或阳性ThyroSeq v3未显著提高恶性率。
- ATA低/中疑结节中,可疑Afirma GSC使恶性率从21.0%升至56.3%。
- ATA低/中疑结节中,阳性ThyroSeq v3使恶性率从24.3%升至66.7%。
核心结论
- Afirma GSC和ThyroSeq v3在超声低/中疑甲状腺结节中排除恶性表现良好,但在超声高疑结节中诊断价值有限。
- 分子检测可预测更具侵袭性的甲状腺癌,从而辅助治疗决策。
研究设计与样本
- 前瞻性队列研究,分析2017年7月至2020年4月在加州大学洛杉矶分校健康系统接受细针穿刺活检的所有Bethesda III和IV甲状腺结节。
- 所有患者作为机构随机试验(NCT02681328)的一部分接受Afirma GSC或ThyroSeq v3分子检测。
- 共纳入343例患者、375个不确定甲状腺结节,按美国甲状腺协会(ATA)超声风险分类分组。
主要发现
- ATA高疑结节中,所有高疑结节恶性率为77.8%,高疑且Afirma GSC可疑者恶性率为87.5%(阳性似然比[LR]=2.0,95%置信区间[CI]0.5-8.0,p=1.0),差异无统计学显著。
- ATA高疑结节中,所有高疑结节恶性率为80.0%,高疑且ThyroSeq v3阳性者恶性率为80.0%(阳性LR=1.0[CI 1.0-1.0],p=1.0),无显著差异。
- ATA低/中疑结节中,Afirma GSC可疑者恶性率从21.0%升至56.3%(阳性LR=4.8[CI 3.4-6.9],p<0.0001),Afirma GSC良性者恶性率降至3.8%(阴性LR=0.1[CI 0.07-0.3],p<0.0001)。
- ATA低/中疑结节中,ThyroSeq v3阳性者恶性率从24.3%升至66.7%(阳性LR=6.2[CI 4.0-9.7],p<0.0001),ThyroSeq v3阴性者恶性率降至2.1%(阴性LR=0.07[CI 0.02-0.3],p<0.0001)。
临床怎么用
- 作者认为,分子检测可预测更具侵袭性的甲状腺癌,从而辅助治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid nodules with indeterminate cytology are increasingly subjected to molecular testing. We evaluated the diagnostic performances of Afirma Genomic Sequencing Classifier (GSC) and ThyroSeq v3 in thyroid nodules with high versus low/intermediate suspicion ultrasound classification. Methods: In this prospective cohort study, we analyzed all Bethesda III and IV thyroid nodules that underwent fine-needle aspiration biopsies in the University of California Los Angeles Health System from July 2017 to April 2020. All patients underwent molecular testing with Afirma GSC or ThyroSeq v3 as part of an institutional randomized trial (NCT02681328). Nodules were categorized according to the American Thyroid Association (ATA) ultrasound risk classification. The benign call rate and the positive predictive value of molecular testing were compared between ATA high suspicion versus all other categories. Results: A total of 343 patients with 375 indeterminate thyroid nodules were included. The malignancy rate in ATA high suspicion nodules was not significantly increased by a suspicious Afirma GSC result (77.8% for all ATA high suspicion nodules vs. 87.5% for nodules with ATA high suspicion and suspicious Afirma GSC results, positive likelihood ratio [LR] = 2.0, 95% confidence interval [CI 0.5-8.0], p = 1.0) or by a positive ThyroSeq v3 result (80.0% vs. 80.0%, positive LR = 1.0 [CI 1.0-1.0], p = 1.0). The rate of malignancy in ATA low/intermediate suspicion nodules increased from 21.0% to 56.3% with a suspicious Afirma GSC result (positive LR = 4.8 [CI 3.4-6.9], p < 0.0001) and decreased to 3.8% with a benign Afirma GSC result (negative LR = 0.1 [CI 0.07-0.3], p < 0.0001). Similarly, the rate of malignancy in ATA low/intermediate suspicion nodules increased from 24.3% to 66.7% with a positive ThyroSeq v3 result (positive LR = 6.2 [CI 4.0-9.7], p < 0.0001) and decreased to 2.1% with a negative ThyroSeq v3 result (negative LR = 0.07 [CI 0.02-0.3], p < 0.0001). Conclusions: Afirma GSC and ThyroSeq v3 performed well in ruling out malignancy in sonographically low/intermediate suspicion thyroid nodules but has limited diagnostic value in sonographically high suspicion nodules. Molecular testing can prognosticate more aggressive thyroid cancers, which can inform treatment decisions.
引用
- Hu TX, Nguyen DT, Patel M, et al. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2022. PMID: 35611970. doi:10.1089/thy.2021.0659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。